Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

European Commission approval granted for TEPKINLY (epcoritamab) + lenalidomide + rituximab (R2) for adults with relapsed/refractory follicular lymphoma, positioning a chemotherapy-free option in the second-line setting. In Phase 3 EPCORE FL-1, epcoritamab + R2 cut the risk of progression or death by 79% (HR 0.21, p<0.0001) vs R2 alone, with ORR rising to 96% (vs 81%) and complete response increasing to 74% (vs 43%). Safety remained consistent with known regimens, with serious adverse reactions at 44% for the epcoritamab combination.

Analysis

This is more valuable as a de-risking event for GMAB’s platform than as an immediate P&L inflection. The market will likely reward the label because it converts a binary oncology story into something closer to a repeatable franchise, but the actual revenue pool in second-line FL is still small enough that the first-order earnings contribution is likely modest. The bigger near-term impact is multiple support: investors can underwrite a higher probability that DuoBody assets continue to win earlier-line approvals, which matters more for GMAB than for the collaboration partner.

Second-order, the approval should pressure incumbents in the sequencing of FL therapy, but the displacement is not clean. A meaningful share of treated patients will still sit on anti-CD20 backbones, so the more important commercial question is whether this combination pulls spend away from community-standard R2 into higher-acuity center-based immunotherapy. If adoption is concentrated in larger European centers, uptake can look strong clinically yet still ramp slowly in revenue terms because reimbursement, logistics, and AE monitoring are the gating factors.

The main risk is that investors extrapolate this into a broad autoimmune-style platform rerating before reimbursement and real-world tolerability are proven. Serious AE burden and CRS monitoring could cap community use, and European pricing processes can delay monetization by quarters. The contrarian view is that the move may be underdone for GMAB’s pipeline credibility but overdone for near-term EPS; for ABBV, this is mostly optionality unless management starts to quantify meaningful ex-U.S. contribution from epcoritamab. Watch whether launch guidance, HTA decisions, and next-indication data keep this as a narrative win or turn it into a durable revenue driver.

Key Decisions for Investors

• Long GMAB on post-release weakness; 1-3 month horizon. Use the approval as a catalyst for multiple expansion rather than for near-term earnings, with upside skew if European launch commentary confirms reimbursement access. Falsify if management frames EU uptake as de minimis or delayed into 2027.
• If you want hedged exposure, pair long GMAB vs. XBI/IBB rather than a single pharma short. The thesis is single-name de-risking and platform validation, not sector beta; the trade should work unless biotech multiples compress broadly on rates or funding conditions.
• Do not add ABBV solely on this headline. Treat the read-through as diluted economics with low EPS sensitivity; reassess only if upcoming guidance starts assigning material contribution from ex-U.S. epcoritamab.
• Set a watch item on Germany/UK HTA and reimbursement timing over the next 1-3 months. Slow pricing access would be the clearest falsifier for the commercial bullish case even if the science remains intact.